Stage 0 Melanoma and the Underwriting Cliff

If you are applying for life insurance after a melanoma in situ, the most important thing to understand is this: to a UK underwriter, "in situ" and "invasive" are not two points on the same scale. They are closer to two different propositions. The word on your discharge letter may be "melanoma", which sounds uniformly frightening, but the line in your histology report that says in situ — meaning stage 0 — is the line the underwriter actually reads, and it changes the whole assessment.

In situ means the abnormal cells had not broken through into the deeper layer of the skin. They were still confined to the surface, where they cannot spread to the rest of the body. Once such a lesion has been fully removed with clear margins, many insurers assess it far more lightly than an invasive melanoma — sometimes close to standard terms after a period — precisely because the thing that makes melanoma dangerous, its ability to spread, had not begun.

That is why being told the melanoma was "caught early" is genuinely good news for your application, but also why it pays to understand exactly what your own report says. The gap between in situ and invasive is a cliff, not a slope, and which side of it you are on is written down.

The short answer: the histology report decides it

When you disclose a melanoma, the underwriter does not price the word. They price the pathology. The single most useful thing you can do is get a copy of your histology report — the pathologist's account of the lesion that was removed — because almost every question that follows is answered on that one document.

It will state whether the melanoma was in situ or invasive. If invasive, it will give the Breslow thickness, the depth of the tumour measured in millimetres, which is the strongest single predictor of outcome. It will say whether the excision margins were clear, meaning no abnormal cells were found at the edges of what was removed. And it will be dated, which lets the underwriter measure how long you have been clear.

This is the same pattern that runs through cancer underwriting generally: the diagnosis word matters far less than the graded detail beneath it. It is the reason that, with a family cancer history, a documented stage at diagnosis tends to beat the genes on a life application — insurers are pricing the specific, evidenced risk, not the headline.

In situ versus invasive: where the boundary sits

The skin has layers. The outer layer, the epidermis, sits on top of the deeper dermis, where the blood vessels and lymphatics run. A melanoma in situ is confined entirely to the epidermis. It has not crossed into the dermis, which means it has had no route to travel elsewhere in the body. This is why it is called stage 0, and why full excision is generally curative.

An invasive melanoma has crossed that boundary. Once cancerous cells reach the dermis, they can in principle reach the lymphatic system and beyond, and the risk of that rises with how deep the tumour has grown. That single structural difference — has it or has it not broken through into the deeper skin — is the whole basis for treating the two so differently, medically and in underwriting.

It is worth saying plainly that an in situ melanoma is still a melanoma and still a serious diagnosis that warrants proper follow-up. It signals that your skin has produced one melanoma and may produce another, so surveillance matters. But in terms of the thing life insurance is pricing — the risk to your life over the policy term — a fully removed stage 0 lesion is in a very different category from an invasive one.

What the underwriter reads off the report

A melanoma disclosure typically triggers a short set of questions, and each maps onto a line in the histology. Being able to answer them from your own copy of the report makes the application smoother and reduces the need for the insurer to chase records.

• In situ or invasive? The threshold question, and the one that most changes the outcome.
• Breslow thickness, if invasive. Measured in millimetres. Thinner lesions carry a better outlook; the rating generally rises with depth.
• Were the margins clear? Clear margins mean the lesion was fully removed. Involved margins may mean further surgery was needed.
• Date of excision. Time matters. The further you are from a clear excision with no recurrence, the more reassuring the picture.
• Any further surgery or investigations. A wider local excision, or a sentinel lymph node biopsy for an invasive lesion, and what they showed.

To confirm these details, an insurer may ask for a consented GP report or hospital records. That is routine, not a warning sign. What you are aiming for is that the report and your answers agree, because the histology is the evidence the whole assessment stands on.

Why the survival gap is so large

The reason underwriters draw such a sharp line is that the survival difference behind it is real and large. Melanoma caught at the very earliest stage has an excellent long-term outlook, while survival falls markedly as an invasive lesion grows deeper and reaches a later stage. Underwriting is, in the end, a translation of that survival curve into terms.

National statistics for England bear the shape of this out: the earlier a melanoma is caught, the higher the survival, with the earliest-stage disease sitting at the top of the range and advanced disease considerably lower. That gradient — not the diagnosis label — is what an underwriter is really responding to when they treat your in situ lesion gently.

Source: NHS England / National Disease Registration Service, Cancer Survival in England, cancers diagnosed 2018 to 2022.

You do not need to memorise figures to use this. The point is simply that the underwriting generosity toward in situ disease is evidence-based, not arbitrary, and that it is your histology — the proof of which side of the gap you are on — that unlocks it.

How each is likely to be assessed

No one can promise you a specific outcome, because insurers set their own thresholds and read your whole file, not just the skin. But the broad shape is predictable enough to be useful.

A melanoma in situ, fully excised with clear margins, is often assessed lightly once a short period has passed, and some applicants reach standard or near-standard terms. The insurer may still ask about ongoing skin surveillance and any further lesions, because the future risk of another melanoma is part of the picture, but the removed lesion itself is not treated as a major mortality risk.

An invasive melanoma is assessed on its depth and the time since it was removed. Thin, early invasive lesions removed some years ago with no recurrence can attract modest terms; thicker or later-stage disease, or a more recent excision, tends to mean a larger loading, a postponement until more time has passed, or in some cases a decline. Because insurers differ, one company's answer is not the market's — and if a decision seems out of step with your histology, you are entitled to ask the insurer what evidence its decision relied on, a right that applies to any decline, not only mental health ones.

You still have to declare it, years later

A common and dangerous assumption is that a skin cancer from long ago, fully treated, no longer counts. Whether it needs declaring depends entirely on how the question is worded, and many life applications ask about any diagnosis of cancer at any time. Where that is the question, an in situ melanoma from a decade ago is disclosable, and leaving it off is a misrepresentation even though the lesion itself was minor.

The reassuring part is that declaring it is very unlikely to be what harms your terms. For an in situ lesion, honest disclosure with the histology detail is what secures the light assessment in the first place. The detail is your friend here: it is exactly what separates a cautious, blanket approach from a properly graded one. A condition-specific diagnosis is far less of an obstacle than people fear once it is documented and dated — the same lesson that applies when people discover that MS affects the cover you want less than you think.

Give the broker the histology

The practical route to good terms after a melanoma in situ is to lead with the evidence. Get your histology report, know your Breslow thickness if there was any invasive component, confirm your margins were clear, and note your excision date and any follow-up. With those facts in hand you can get life insurance quotes and let an FCA-authorised broker place the case with insurers whose thresholds suit an early skin cancer, rather than applying blind to one company and taking its single answer as final.

It also helps to know that life cover does not quietly carve out conditions you already have the way health insurance can — a fear that stops some people applying at all. It is worth reading why life cover has no moratorium and you are thinking of private medical insurance before you assume a past melanoma means cover that will never respond. For the wider picture of how histories and conditions are handled, our guide to getting cover with a history, a condition or a job covers the same ground across other diagnoses.

Scotland and Northern Ireland

How a melanoma is underwritten does not change across the UK — the histology means the same thing to an insurer in Glasgow as in Cardiff. What differs is the law governing the medical reports an insurer may seek to confirm your history.

In England, Wales and Scotland, your right to see a report prepared by your own doctor before it goes to the insurer comes from the Access to Medical Reports Act 1988. Northern Ireland uses its own version, the Access to Personal Files and Medical Reports (Northern Ireland) Order 1991. Under either, when you give consent for a GP or hospital report you can ask to see it first and to correct any factual error — useful when the accuracy of a single histology line carries as much weight as it does here.

Frequently asked questions

Is melanoma in situ treated as cancer by insurers?

It is disclosed as a skin cancer, but underwriters treat it very differently from invasive melanoma. In situ means the abnormal cells had not spread beyond the top layer of skin. Once fully excised with clear margins, many insurers assess it far more lightly than an invasive lesion, and some applicants reach standard or near-standard terms after a short period.

What will the insurer want to see?

The histology report is the key document: whether the lesion was in situ or invasive, the Breslow thickness if invasive, whether the margins were clear, the date of excision and any further surgery. A consented GP report or hospital records may be requested to confirm those details, so it helps to have your own copy of the histology to hand when you apply.

Do I still have to declare it years later?

Yes, if the question asks about any diagnosis of cancer whatever the date, as many do. Answer what is asked accurately and give the histology detail, because that detail is exactly what separates a light assessment from a heavy one in the underwriter's hands. Declaring an in situ lesion is rarely what harms your terms — the documented detail is what secures the lighter view.